Public dataset
Recorded enzyme and transporter findings by polarity
Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.
What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
- Public rows
- 8,404
- Generated
- Schema version
- 1.3.0
Coverage
What this run contains
- Medicine–counterparty–role groups
- 8,404
- Source sentence records
- 20,358
- Asserted sentences
- 4,700
- Denied sentences
- 7,494
- Polarity not recorded
- 8,164
- Medicines represented
- 755
- Counterparties represented
- 36
- Corpus records considered
- 9,855
- All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
- inducer groups
- 617
- inhibitor groups
- 3,131
- not_recorded groups
- 3,074
- substrate groups
- 1,582
Method
How the rows were made
- A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
- A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
- Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
- Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
- The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.
Limits
Read these before using a row
- A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
- This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
- ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
- A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
- 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
- Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
- 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
- 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
- The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
- The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
- A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
- Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.
Provenance
Source examples
Abacavir · CYP3A4 inhibitor
2 asserted · 2 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.
Abacavir · BCRP substrate
0 asserted · 4 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.
Abacavir · CYP2C9 not_recorded
0 asserted · 0 denied · 2 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).
Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| medicineName | string | Recorded medicine name; not normalized for display style. |
| counterparty | string | The exact recorded counterparty spelling. |
| role | string | SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role. |
| assertedCount | number | Sentence records whose polarity is ASSERTED. |
| deniedCount | number | Sentence records whose polarity is NEGATED. |
| polarityNotRecordedCount | number | Sentence records for which the parser did not settle assertion or denial. |
| sentences | sentence[] | Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated. |
Reader
Search and filter the rows
Showing 201–210 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 201
- Medicine slug
- alogliptin
- Medicine name
- Alogliptin
- Enzyme or transporter
- CYP2C9
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
Projected row 202
- Medicine slug
- alogliptin
- Medicine name
- Alogliptin
- Enzyme or transporter
- CYP2D6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
Projected row 203
- Medicine slug
- alogliptin
- Medicine name
- Alogliptin
- Enzyme or transporter
- CYP3A4
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin In Vitro Studies Effect of Alogliptin on CYP Enzymes Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.
Projected row 204
- Medicine slug
- alogliptin
- Medicine name
- Alogliptin
- Enzyme or transporter
- P-GP
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Alogliptin had no significant effect on the prothrombin time (PT) or International Normalized Ratio (INR). **Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate) and fexofenadine (P-gp substrate) were administered as a cocktail.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:f2ad6d21-8060-42c7-8b3f-ad80085dc022 (opens source in a new tab)
Alogliptin label
Version not recorded · Effective date not recorded
Alogliptin had no significant effect on the prothrombin time (PT) or International Normalized Ratio (INR). **Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate) and fexofenadine (P-gp substrate) were administered as a cocktail.
Projected row 205
- Medicine slug
- alosetron
- Medicine name
- Alosetron
- Enzyme or transporter
- CYP1A2
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
Alosetron label
Version not recorded · Effective date not recorded
However, in vivo data suggest that CYP1A2 plays a more prominent role in alosetron metabolism (62% to 97% of alosetron clearance) based on correlation of alosetron clearance with in vivo CYP1A2 activity measured by probe substrate, increased clearance induced by smoking and inhibition of clearance by fluvoxamine [see Contraindications (4) , Drug Interactions (7) ] .
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:3ac203a2-4c55-deac-e063-6394a90aa165 (opens source in a new tab)
Alosetron label
Version not recorded · Effective date not recorded
However, in vivo data suggest that CYP1A2 plays a more prominent role in alosetron metabolism (62% to 97% of alosetron clearance) based on correlation of alosetron clearance with in vivo CYP1A2 activity measured by probe substrate, increased clearance induced by smoking and inhibition of clearance by fluvoxamine [see Contraindications (4) , Drug Interactions (7) ] .
Projected row 206
- Medicine slug
- alpelisib
- Medicine name
- Alpelisib
- Enzyme or transporter
- BCRP
- Role
- INHIBITOR
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
Alpelisib has a low potential to inhibit BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K at clinically relevant concentrations.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
Alpelisib has a low potential to inhibit BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K at clinically relevant concentrations.
Projected row 207
- Medicine slug
- alpelisib
- Medicine name
- Alpelisib
- Enzyme or transporter
- BCRP
- Role
- SUBSTRATE
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
In Vitro Studies Effect of Transporter on Alpelisib: Alpelisib is a substrate of BCRP.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
In Vitro Studies Effect of Transporter on Alpelisib: Alpelisib is a substrate of BCRP.
Projected row 208
- Medicine slug
- alpelisib
- Medicine name
- Alpelisib
- Enzyme or transporter
- BSEP
- Role
- INHIBITOR
- Asserted sentences
- 2
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
Alpelisib has a low potential to inhibit BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K at clinically relevant concentrations.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
Alpelisib has a low potential to inhibit BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OCT1, OAT1, OAT3, OCT2, MATE1, and MATE2K at clinically relevant concentrations.
Projected row 209
- Medicine slug
- alpelisib
- Medicine name
- Alpelisib
- Enzyme or transporter
- CYP2B6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 Substrates: Coadministration of repeated doses of alpelisib 300 mg with a single-dose of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion), administered as a cocktail did not show clinically significant pharmacokinetic interactions.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 Substrates: Coadministration of repeated doses of alpelisib 300 mg with a single-dose of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion), administered as a cocktail did not show clinically significant pharmacokinetic interactions.
Projected row 210
- Medicine slug
- alpelisib
- Medicine name
- Alpelisib
- Enzyme or transporter
- CYP2C19
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 Substrates: Coadministration of repeated doses of alpelisib 300 mg with a single-dose of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion), administered as a cocktail did not show clinically significant pharmacokinetic interactions.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b (opens source in a new tab)
Alpelisib label
Version not recorded · Effective date not recorded
CYP3A4, CYP2C8, CYP2C9, CYP2C19 and CYP2B6 Substrates: Coadministration of repeated doses of alpelisib 300 mg with a single-dose of sensitive substrates of CYP3A4 (midazolam), CYP2C8 (repaglinide), CYP2C9 (warfarin), CYP2C19 (omeprazole) and CYP2B6 (bupropion), administered as a cocktail did not show clinically significant pharmacokinetic interactions.
Access
Query or download the projection
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=200Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- role
- Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
- counterparty
- Exact recorded counterparty spelling.
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.